Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read Healthcare Industry News Why HeartBeam’s 510(k) appeal could reshape cardiac software approval timelines HeartBeam outlines a dual-track regulatory strategy after FDA setback on ECG software. See how it plans to unlock clearance and stay on track for market entry. byPallavi MadhirajuNovember 28, 2025